Kinase Inhibitor [EPC]

557577 reported adverse events

Drugs of this class: SIROLIMUS EVEROLIMUS NILOTINIB GEFITINIB SORAFENIB AXITINIB PALBOCICLIB ACALABRUTINIB BOSUTINIB LAROTRECTINIB LORLATINIB

These side effects are most commonly reported by patients taking drugs of the Kinase Inhibitor [EPC] class:

# Side effect Count
0 DEATH 60120
1 FATIGUE 50171
2 DIARRHOEA 46391
3 OFF LABEL USE 39850
4 NAUSEA 31657
5 MALIGNANT NEOPLASM PROGRESSION 20889
6 ASTHENIA 19725
7 DECREASED APPETITE 18615
8 RASH 17676
9 VOMITING 17378
See all common reactions for Kinase Inhibitor [EPC]

Drugs of the Kinase Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 ACQUIRED GENE MUTATION 671 0.5118
1 NEOPLASM PROGRESSION 16263 0.4672
2 MYELOFIBROSIS 1013 0.3347
3 METASTASES TO MENINGES 712 0.3128
4 TUMOUR MARKER INCREASED 1377 0.2867
5 HEPATOCELLULAR CARCINOMA 2026 0.2662
6 NON-SMALL CELL LUNG CANCER 1212 0.2528
7 PARONYCHIA 1067 0.2426
8 WHITE BLOOD CELL COUNT ABNORMAL 1539 0.2409
9 METASTASES TO CENTRAL NERVOUS SYSTEM 3095 0.2397
See all enriched reactions for Kinase Inhibitor [EPC]